Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Grace Therapeutics, Inc.
13G
GRCE · 00439U104
|
13.1% |
8/7/2026
Event 8/5/2026
|
|||
| Opaleye Management Inc. | 13.1% | ||||
| Opaleye, L.P. | 13.1% | ||||
| James Silverman | 13.1% | ||||
|
Pasithea Therapeutics Corp.
13G/A
Amendment 1
KTTA · 70261F202
|
6.1% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 6.1% | ||||
| Opaleye, L.P. | 6.1% | ||||
| James Silverman | 6.1% | ||||
|
Harrow, Inc.
13G/A
Amendment 9
HROW · 415858109
|
6.4% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 6.4% | ||||
| Opaleye, L.P. | 6.4% | ||||
| James Silverman | 6.4% | ||||
|
SANUWAVE Health, Inc.
13G/A
Amendment 7
SNWV · 80303D305
|
3.6% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 3.6% | ||||
| Opaleye, L.P. | 3.6% | ||||
| James Silverman | 3.6% | ||||
|
Q32 Bio Inc.
13G/A
Amendment 2
QTTB · 746964105
|
5.5% |
7/31/2026
Event 6/30/2026
|
|||
| Opaleye Management Inc. | 5.5% | ||||
| Opaleye, L.P. | 5.5% | ||||
| James Silverman | 5.5% | ||||
|
Gossamer Bio, Inc.
13G
GOSS · 38341P102
|
5.1% |
7/29/2026
Event 7/22/2026
|
|||
| Opaleye Management Inc. | 5.1% | ||||
| Opaleye, L.P. | 4.9% | ||||
| James Silverman | 5.1% | ||||
|
Alpha Cognition Inc.
13G/A
Amendment 7
ACOG · 02074J501
|
14.2% |
7/24/2026
Event 7/23/2026
|
|||
| Opaleye Management Inc. | 14.2% | ||||
| Opaleye, L.P. | 13.8% | ||||
| James Silverman | 14.2% | ||||
|
Alpha Cognition Inc.
13G/A
Amendment 6
ACOG · 02074J501
|
13.3% |
6/29/2026
Event 6/26/2026
|
|||
| Opaleye Management Inc. | 13.3% | ||||
| Opaleye, L.P. | 12.9% | ||||
| James Silverman | 13.3% | ||||
|
Alpha Cognition Inc.
13G/A
Amendment 5
ACOG · 02074J501
|
12.0% |
5/22/2026
Event 5/21/2026
|
|||
| Opaleye Management Inc. | 12.0% | ||||
| Opaleye, L.P. | 11.6% | ||||
| James Silverman | 12.0% | ||||
|
Rezolute, Inc.
13G/A
Amendment 2
RZLT · 76200L309
|
6.6% |
5/11/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 6.6% | ||||
| Opaleye, L.P. | 6.4% | ||||
| James Silverman | 6.6% | ||||
|
Karyopharm Therapeutics Inc.
13G/A
Amendment 1
KPTI · 48576U205
|
2.7% |
5/11/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 2.7% | ||||
| Opaleye, L.P. | 2.7% | ||||
| James Silverman | 2.7% | ||||
|
Harrow, Inc.
13G/A
Amendment 8
HROW · 415858109
|
7.6% |
5/11/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 7.6% | ||||
| Opaleye, L.P. | 7.5% | ||||
| James Silverman | 7.6% | ||||
|
Alpha Cognition Inc.
13G/A
Amendment 4
ACOG · 02074J501
|
11.8% |
5/11/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 11.8% | ||||
| Opaleye, L.P. | 11.4% | ||||
| James Silverman | 11.8% | ||||
|
Q32 Bio Inc.
13G/A
Amendment 1
QTTB · 746964105
|
8.6% |
5/6/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 8.6% | ||||
| Opaleye, L.P. | 8.6% | ||||
| James Silverman | 8.6% | ||||
|
Sol-Gel Technologies Ltd
13G/A
Amendment 4
SLGL · M8694L137
|
15.4% |
5/6/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 15.4% | ||||
| Opaleye, L.P. | 14.9% | ||||
| James Silverman | 15.4% | ||||
|
Codexis, Inc.
13G/A
Amendment 4
CDXS · 192005106
|
7.5% |
5/5/2026
Event 3/31/2026
|
|||
| Opaleye Management Inc. | 7.5% | ||||
| Opaleye, L.P. | 7.3% | ||||
| James Silverman | 7.5% | ||||
|
SANUWAVE Health, Inc.
13G/A
Amendment 6
SNWV · 80303D305
|
10.0% |
5/4/2026
Event 5/1/2026
|
|||
| Opaleye Management Inc. | 10.0% | ||||
| Opaleye, L.P. | 9.9% | ||||
| James Silverman | 10.0% | ||||
|
Pasithea Therapeutics Corp.
13G
KTTA · 70261F202
|
10.0% |
4/8/2026
Event 4/1/2026
|
|||
| Opaleye Management Inc. | 10.0% | ||||
| Opaleye, L.P. | 10.0% | ||||
| James Silverman | 10.0% | ||||
|
Sol-Gel Technologies Ltd
13G/A
Amendment 3
SLGL · M8694L137
|
16.5% |
3/23/2026
Event 2/13/2026
|
|||
| Opaleye Management Inc. | 16.5% | ||||
| Opaleye, L.P. | 16.2% | ||||
| James Silverman | 16.5% | ||||
|
Alpha Cognition Inc.
13G/A
Amendment 3
ACOG · 02074J501
|
11.0% |
3/4/2026
Event 3/2/2026
|
|||
| Opaleye Management Inc. | 11.0% | ||||
| Opaleye, L.P. | 10.6% | ||||
| James Silverman | 11.0% | ||||
|
Alpha Cognition Inc.
13G/A
Amendment 2
ACOG · 02074J501
|
10.1% |
2/20/2026
Event 2/19/2026
|
|||
| Opaleye Management Inc. | 10.1% | ||||
| Opaleye, L.P. | 9.8% | ||||
| James Silverman | 10.1% | ||||
|
Q32 Bio Inc.
13G
QTTB · 746964105
|
8.7% |
2/20/2026
Event 2/19/2026
|
|||
| Opaleye Management Inc. | 8.7% | ||||
| Opaleye, L.P. | 8.7% | ||||
| James Silverman | 8.7% | ||||
|
Alpha Cognition Inc.
13G/A
Amendment 1
ACOG · 02074J501
|
10.4% |
2/20/2026
Event 2/19/2026
|
|||
| Opaleye Management Inc. | 10.4% | ||||
| Opaleye, L.P. | 10.1% | ||||
| James Silverman | 10.4% | ||||
|
Alpha Cognition Inc.
13G
ACOG · 02074J501
|
9.5% |
2/6/2026
Event 12/31/2025
|
|||
| Opaleye Management Inc. | 9.5% | ||||
| Opaleye, L.P. | 9.3% | ||||
| James Silverman | 9.5% | ||||
|
Codexis, Inc.
13G/A
Amendment 3
CDXS · 192005106
|
7.5% |
1/23/2026
Event 12/31/2025
|
|||
| Opaleye Management Inc. | 7.5% | ||||
| Opaleye, L.P. | 7.4% | ||||
| James Silverman | 7.5% | ||||
|
Rezolute, Inc.
13G
RZLT · 76200L309
|
5.3% |
12/19/2025
Event 12/12/2025
|
|||
| Opaleye Management Inc. | 5.3% | ||||
| Opaleye, L.P. | 5.2% | ||||
| James Silverman | 5.3% | ||||
|
Codexis, Inc.
13G/A
Amendment 2
CDXS · 192005106
|
10.0% |
12/5/2025
Event 12/3/2025
|
|||
| Opaleye Management Inc. | 10.0% | ||||
| Opaleye, L.P. | 9.8% | ||||
| James Silverman | 10.0% | ||||
|
Sol-Gel Technologies Ltd
13G/A
Amendment 2
SLGL · M8694L137
|
13.2% |
11/17/2025
Event 11/13/2025
|
|||
| Opaleye Management Inc. | 13.2% | ||||
| Opaleye, L.P. | 12.8% | ||||
| James Silverman | 13.2% | ||||
|
Sol-Gel Technologies Ltd
13G/A
Amendment 1
SLGL · M8694L137
|
7.4% |
11/14/2025
Event 9/30/2025
|
|||
| Opaleye Management Inc. | 7.4% | ||||
| Opaleye, L.P. | 7.4% | ||||
| James Silverman | 7.4% | ||||
|
Karyopharm Therapeutics Inc.
13G
KPTI · 48576U205
|
9.5% |
10/17/2025
Event 10/10/2025
|
|||
| Opaleye Management Inc. | 9.5% | ||||
| Opaleye, L.P. | 9.5% | ||||
| James Silverman | 9.5% | ||||
|
Alpha Cognition Inc.
13G
ACOG · 02074J501
|
9.0% |
10/3/2025
Event 10/1/2025
|
|||
| Opaleye Management Inc. | 9.0% | ||||
| Opaleye, L.P. | 9.0% | ||||
| James Silverman | 9.0% | ||||
|
Sol-Gel Technologies Ltd
13G
SLGL · M8694L137
|
5.0% |
8/29/2025
Event 8/22/2025
|
|||
| Opaleye Management Inc. | 5.0% | ||||
| Opaleye, L.P. | 5.0% | ||||
| James Silverman | 5.0% | ||||
|
Larimar Therapeutics, Inc.
13G
LRMR · 517125100
|
4.8% |
8/29/2025
Event 8/29/2025
|
|||
| Opaleye Management, Inc. | 4.8% | ||||
| Opaleye, L.P. | 4.8% | ||||
| James Silverman | 4.8% | ||||
|
Protara Therapeutics, Inc.
13G/A
Amendment 2
TARA · 74365U107
|
4.7% |
4/28/2025
Event 3/31/2025
|
|||
|
Larimar Therapeutics, Inc.
13G
LRMR · 517125100
|
6.2% |
4/16/2025
Event 4/9/2025
|
|||
| Opaleye Management, Inc. | 6.2% | ||||
| Opaleye, L.P. | 6.2% | ||||
| James Silverman | 6.2% | ||||
|
Ocular Therapeutix, Inc
13G/A
Amendment 6
OCUL · 67576A100
|
2.8% |
2/14/2025
Event 12/31/2024
|
|||
|
iBio, Inc.
13G/A
Amendment 1
IBIO · 451033708
|
7.6% |
2/14/2025
Event 12/31/2024
|
|||
|
Protara Therapeutics, Inc.
13G/A
Amendment 1
TARA · 74365U107
|
5.3% |
2/14/2025
Event 12/31/2024
|
|||
|
Context Therapeutics Inc.
13G/A
Amendment 1
CNTX · 21077P108
|
0% |
2/14/2025
Event 12/31/2024
|
|||